Vistide
cidofovir
Table of contents
Overview
The marketing authorisation for Vistide has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Vistide
|
| Agency product number |
EMEA/H/C/000121
|
| Active substance |
cidofovir
|
| International non-proprietary name (INN) or common name |
cidofovir
|
| Therapeutic area (MeSH) |
Cytomegalovirus Retinitis
|
| Anatomical therapeutic chemical (ATC) code |
J05AB12
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Gilead Sciences International Limited
|
| Revision |
21
|
| Date of issue of marketing authorisation valid throughout the European Union |
23/04/1997
|
| Contact address |
Cambridge
CB21 6GT United Kingdom |
Product information
22/08/2014 Vistide - EMEA/H/C/000121 - N/0034
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antivirals for systemic use
Therapeutic indication
Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable.